Kedrion Biopharma, an Italian biotech company, has started the development of a plasma-derived therapy for treating the COVID-19 virus that could make it available to patients in as little as three to six months.  Alessandro Gringeri, Chief Medical and R&D Officer of Kedrion Biopharma, said the company, the world’s fifth largest in plasma products, has been pouring investment and research resources into the effort, and expects to collect plasma from convalescent patients in the next...